Macquarie Group’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Macquarie Group’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-381,785	Closed	-$21.5M	–	2547
2017 Q4	$21.5M	Buy	381,785 +56,291	+17%	+$3.08M	0.04%	458
2017 Q3	$18.6M	Sell	325,494 -3,280	-1%	-$192K	0.03%	466
2017 Q2	$19.8M	Sell	328,774 -279,099	-46%	-$15.9M	0.04%	449
2017 Q1	$33.1M	Buy	+607,873	New	+$29.9M	0.06%	298

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Macquarie Group's BIVV Position: Q1 2018 in Review

Macquarie Group sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 381,785 shares — an estimated $21.5M sold.

Macquarie Group first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $33.1M in Q1 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Macquarie Group reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Macquarie Group sold 381,785 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $21.5M.
Macquarie Group first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Macquarie Group's Bioverativ Inc. Common Stock position peaked at $33.1M in Q1 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.